Accuracy of Implant Placement for Patients With Mandibular Reconstruction Using Dynamic Navigation and Static Guides
Evaluation of Accuracy of Implant Placement for Patients With Mandibular Reconstruction Using Dynamic Navigation Compared to Static Guides: a Parallel, Randomized Controlled Clinical Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female patients between the ages of 18 and 70 (inclusive)
- Mandibular defects (including Class I defects, limited to the body of the mandible; Class II defects, muscular-mandibular region defects and Class III defects, chin protrusion-muscular-mandibular region defects), which have been reconstructed by mandibular vascularization of free iliac bone, and fibular composite muscular flap grafts for greater than 3 months
- Normal mouth opening (≥ 40 mm)
- Trialists voluntarily signed an informed consent form before performing any research-related experimental steps.
Exclusion Criteria:
- Presence of localized inflammation in adjacent teeth, including uncontrolled periodontitis (periodontal probing to a depth of >4 mm)
- Presence of untreated acute and chronic apical periodontitis in adjacent teeth
- Oral mucosal lesions (e.g., lichen planus)
- Adjacent teeth with space-occupying lesions (including cysts, tumors, etc.)
- Systemic diseases affecting bone healing, wound healing and dental implant treatment (e.g., uncontrolled diabetes mellitus, fasting blood glucose ≥ 8.8 mmol/L despite medication)
- Uncontrolled and unstabilized severe hypertension
- Contraindications to routine implant surgery and oral surgery
- Heart disease (Class II or above)
- Patients with liver or kidney insufficiency or abnormality
- Obese patients with body mass index (BMI) > 28 kg/m2
- Patients with a history of full-dose radiotherapy, localized radiotherapy to the head or neck
- Patients requiring long-term high-dose steroid therapy
- Patients who are receiving or have received in the last 3 months medications (e.g., bisphosphonates) that may affect or promote bone metabolism
- Consecutive antibiotic therapy or chronic anti-inflammatory therapy (≥3 times per week) within the first 4 weeks of starting the procedure
- Alcohol or chronic substance abuse
- Immunocompromised patients
- Smoking/tobacco equivalents/chewing tobacco >10 cigarettes per day
- Physical or mental impairment that interferes with the performance of oral hygiene care
- Female patients who are pregnant or breastfeeding
- Patients who, in the opinion of the investigator, have poor compliance and cannot participate in the trial
- Patients who have participated in a clinical trial of another drug or device within 30 days prior to the start of the procedure (Study Day 0)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dynamic navigation
|
Osteotomy and implant placement with the guidance of dynamic navigation
|
|
Active Comparator: Static template
|
Osteotomy and implant placement with the guidance of static template
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Three-dimensional implant placement accuracy of apical point
Time Frame: Postoperative day 2±1
|
The postoperative cone beam computed tomography (CBCT) was aligned to the preoperative plan in specific software, and the three-dimensional coordinates of the preoperatively planned and actual postoperative implant placement positions were measured separately, from which the three-dimensional distance (in mm) between the apical point of the actual implant and the apical point of the virtual implant was calculated.
|
Postoperative day 2±1
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Three-dimensional implant placement accuracy of coronal point
Time Frame: Postoperative day 2±1
|
The postoperative CBCT was aligned to the preoperative plan in specific software, and the three-dimensional coordinates of the preoperatively planned and actual postoperative implant placement positions were measured separately, from which the three-dimensional distance (in mm) between the coronal point of the actual implant and the coronal point of the virtual implant was calculated.
|
Postoperative day 2±1
|
|
Three-dimensional implant placement angular accuracy
Time Frame: Postoperative day 2±1
|
The postoperative CBCT was aligned to the preoperative implant placement plan in specific software to measure the three-dimensional coordinates of the preoperative plan and the actual postoperative implant placement position, respectively, and to calculate the angle (°) between the actual implant and the mid-axis of the virtual implant accordingly.
|
Postoperative day 2±1
|
|
Operation time
Time Frame: Intraoperative
|
From the beginning of anesthesia to the complete removal of the static template or navigation reference frame.
|
Intraoperative
|
|
Patient subjective satisfaction
Time Frame: Postoperative day 14±1
|
Evaluating patient satisfaction with the visual analogue scale
|
Postoperative day 14±1
|
|
Failure rate during implant healing period
Time Frame: Postoperative day 90±7
|
1.
According to the definition of Albrektsson and Zarb in 1986, the healing period is considered successful if the following conditions are met: no loosening of the implant after removal of the upper restoration; no peri-implant radiolucency; no peri-implant bone instability; and no pain.
Implant retention was evaluated according to three levels: good osseointegration, poor osseointegration, and implant failure.
2. Implant survival rate = (N total - N failure)/(N total) × 100%.
|
Postoperative day 90±7
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SDC-24-2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.